DRUG · Unmapped registry intervention
SBT6050
Find medicine records ·
Find other trials using this name
Clinical trial
A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
NCT04460456
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
pembrolizumab
Normalized identity: pembrolizumabView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Cemiplimab
Normalized identity: cemiplimabView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
HER2 Positive Solid Tumorsunresolved
Interventions
SBT6050DRUG
pembrolizumabDRUG · verified · RxNorm: pembrolizumab
CemiplimabDRUG · verified · RxNorm: cemiplimab
Sponsors & collaborators
Silverback Therapeuticslead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04460456 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.